Racenil

Quick links to important sections

Racenil

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Racenil

Quick Facts

Property Description
Active ingredient Racecadotril
Form Hard capsules, Granules for oral suspension (sachets)
Pharmacological class Antisecretory Agent (Enkephalinase Inhibitor)
General purpose Symptomatic relief from acute watery diarrhea
Origin Synthetic prodrug

What is Racenil? Identity and Composition

Racenil is a single-ingredient medicinal product, the definition of which is centered on its International Nonproprietary Name (INN), Racecadotril. This substance is identified as a synthetic prodrug, meaning it is chemically manufactured and inactive upon ingestion, requiring the body to convert it into its effective metabolite, Thiorphan. The medicine is formulated for oral administration and is positioned for use across various age groups, with granules for oral suspension being the primary form for pediatric patients, alongside hard capsules typically used by adults.

Racenil's Pharmacological Class: Antisecretory Agents

Racecadotril is pharmacologically classified as an antisecretory agent, belonging to the class of enkephalinase inhibitors. This categorization defines its action as a targeted modulation of fluid and electrolyte processes in the intestine, distinguishing it from anti-diarrheal agents that work by suppressing intestinal movement.

Its general therapeutic purpose is to provide symptomatic relief for acute diarrhea by mitigating the underlying issue of excessive fluid and electrolyte loss. The use of Racecadotril in this context is recognized for its ability to reduce stool output, making it a functional option for managing the watery stool characteristic of acute fluid imbalance. The medicine achieves this by selectively protecting natural compounds (enkephalins) that inherently reduce intestinal hypersecretion, thereby aiding the body in restoring fluid balance without interfering with the gut's normal contractile function.

What side effects are possible with Racenil?

Possible side effects and safety information

The officially documented safety profile of Racecadotril is structured around established system-organ classes and frequency classifications, consistent with government regulatory texts such as the Summary of Product Characteristics (SmPC) and equivalent labeling. Adverse reactions are grouped by incidence based on data from clinical trials and post-marketing surveillance.

Frequency Classification of Adverse Reactions

Adverse reactions are classified by incidence:

Classification Example Reaction System-Organ Class
Common (ge 1/100 to < 1/10) Headache Nervous system disorders
Uncommon (ge 1/1,000 to < 1/100) Rash, Erythema, Tonsillitis Skin, Infections
Frequency Not Known Angioedema, Anaphylactic shock, SCARs Immune system, Skin

Reactions classified as Frequency Not Known include serious hypersensitivity events such as Angioedema (swelling of the face, lips, or tongue) and Severe Cutaneous Adverse Reactions (SCARs), including Drug reaction with eosinophilia and systemic symptoms (DRESS). These reactions may occur at any time during therapy.

Population-Specific Safety Considerations

The official labeling notes specific constraints regarding use in certain populations:

  • Hepatic and Renal Impairment: Caution is advised for adults, and the medicine is not to be administered to children with pre-existing hepatic or renal impairment due to a lack of specific safety data.
  • Pregnancy and Lactation: The medicine should not be administered to pregnant or breastfeeding women, as clinical studies in these groups are unavailable.
  • Safety Constraints: Use is restricted in cases of acute dysentery (indicated by bloody or purulent stools and fever). Co-administration with Angiotensin-Converting Enzyme (ACE) inhibitors is associated with an increased risk of angioedema.

Overdose and Emergency Response

The official regulatory profile for Racenil (Racecadotril) overdose is defined by its substantial documented safety margin in acute settings. Government prescribing information explicitly states that no cases of symptomatic overdose have been formally reported in clinical studies or post-marketing surveillance. This is supported by data showing that adult subjects tolerated single doses exceeding 2 grams, which is equivalent to approximately 20 times the therapeutic dose, without any described harmful effects.

Due to this finding, regulatory documents do not detail specific clinical signs, physiological findings, or severe outcomes resulting from overdose. The documented high-dose tolerance data is noted to be specific to the adult population.

When to Seek Help

Any suspected Racenil overdose requires seeking immediate medical attention. Management of the overdose situation must follow recognised procedures for supportive and symptomatic care, as mandated by regulatory authorities. The official labeling confirms that no specific antidote has been identified for Racecadotril. No specific hospital monitoring or observation protocols are mandated within the official overdose summary. This emphasis on general management reflects the minimal toxicity reported in high-dose exposures.

Therapeutic Uses of Racenil

What Racenil Treats: Main Uses and Benefits

The primary role of Racenil is to provide symptomatic relief for acute diarrhea in adults and children over three months of age. This therapy may be used alongside standard care to support the resolution of symptoms and help manage issues related to high stool volume.

Racenil is used for managing symptoms related to heightened physiological activity, specifically symptoms related to fluid and electrolyte imbalance, such as watery, loose stools. The main therapeutic benefit is that it is applied in addressing the symptom clusters of high stool frequency and volume, which provides support that helps ease the overall burden of symptoms.

The common clinical indications include the symptomatic treatment of acute, sudden-onset diarrhea in adults, children, and infants, often applied in scenarios where short-term symptomatic assistance is needed. This allows for supportive relief when symptoms interfere with routine activities.

“The medication is generally applied when symptoms become momentarily overwhelming, offering support that helps patients cope more steadily.”


Quick Fact: Relief for Acute Watery Stools

Property Description
Primary Symptom Domain Symptoms of high volume and frequency of watery stools
Target Condition Category Acute, sudden-onset diarrheal episodes
Main Patient Benefit Supports easing overall symptom burden, assists with maintaining functional stability
Therapeutic Context Adjunctive to Oral Rehydration Therapy (ORS)

Eligibility and Restrictions for Use

Who Can and Cannot Use Racenil?

Eligibility for Racenil (Racecadotril) is defined by regulatory bodies based on age, physiological status, and underlying conditions. The medicine is primarily intended for adults and children over three months of age for the symptomatic treatment of acute diarrhea.

Contraindicated Populations and Restrictions

Official labeling strictly prohibits the use of Racenil in specific patient groups:

Classification Population/Condition
Absolute Contraindication Infants under three months of age (safety/efficacy not established).
Absolute Contraindication Individuals with known hypersensitivity to Racecadotril or its excipients, including those with rare hereditary galactose or glucose malabsorption disorders.
Not Recommended Diarrhea associated with bloody or purulent stools or high fever, as well as chronic or antibiotic-associated diarrhea (insufficient testing).

Use Limitations

Use is restricted for certain physiological states:

  • Pregnancy and Lactation: Racenil should not be administered during pregnancy or breastfeeding due to a lack of sufficient human clinical data.
  • Organ Impairment: Caution is advised in patients with hepatic impairment (liver failure) or renal impairment (kidney failure). The medicine must not be administered to children with any degree of liver or kidney impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The officially documented interaction profile for Racenil (Racecadotril) is defined primarily by a pharmacodynamic risk, alongside documented minimal pharmacokinetic interaction potential.

Documented Interaction Restrictions

Co-administration with Angiotensin-Converting Enzyme (ACE) Inhibitors is formally contraindicated in patients with a prior documented history of angioedema while taking an ACE Inhibitor. This restriction is due to the potential for a combined effect that increases the risk of bradykinin-mediated events. Regulatory documents advise caution when Racecadotril is co-administered with other drug classes known to cause bradykinin-mediated angioedema, including Angiotensin II Antagonists, mTOR Inhibitors, and certain Gliptins.

Pharmacokinetic Profile

Official regulatory data indicate that Racecadotril has a low potential for clinically relevant pharmacokinetic interactions. In regulatory assessments, Racecadotril and its active metabolite do not inhibit or induce major CYP or UGT metabolic enzymes to a significant extent. The medicine does not modify the kinetics of co-administered substances such as Loperamide or Nifuroxazide, nor does it alter the protein binding of highly-bound drugs like Warfarin.

Food and Population Considerations

Ingestion with food is documented to delay the time to maximum plasma concentration ( T max) of the active metabolite by 60 to 90 minutes, though the overall drug exposure (AUC) remains unaffected. Caution is advised for patients with renal or hepatic impairment, as official data regarding interactions and exposure alterations in these specific populations are limited.

Mechanism of Action

How Racenil Works

The mechanism of action for Racenil operates at the molecular level, resulting in an inhibition of intestinal hypersecretion within the gastrointestinal tract. The drug's action is defined by a highly specific, enzyme-based cascade that modulates the intestine's regulatory mechanisms for fluid balance.


Enzyme Inhibition and Protection of Natural Peptides

The medicine's active metabolite, Thiorphan, functions as a highly specific competitive inhibitor of the enzyme Neutral Endopeptidase (NEP), which is concentrated on the surface of intestinal lining cells. This inhibition prevents the breakdown of endogenous enkephalins (natural opioid-like peptides), allowing their local concentration to rise, thereby increasing the activation of delta-opioid receptors in the gut wall.


Targeted Modulation of Intestinal Secretion

The protected enkephalins activate delta-opioid receptors, initiating an intracellular cascade that reduces levels of the signaling molecule cAMP within the epithelial cells. This reduction in cAMP directly modulates the function of chloride channels (such as the CFTR channel), limiting the excessive secretion of chloride ions and subsequently, water into the intestinal lumen. The mechanism results in a limitation of pathological fluid output without affecting normal intestinal motility or central nervous system activity, as the drug does not cross the blood-brain barrier.

Dosage and Administration Information

Racenil is administered exclusively via the oral route, with the appropriate form determined by the patient’s age. Adults and adolescents (ge 15 years) use the 100 mg hard capsules, while infants and children (ge 3 months) are prescribed the 10 mg or 30 mg granules for oral suspension.

The dosing regimen begins with a single initial dose, followed by maintenance administration three times daily (TID) at regular intervals. For adults, this involves taking one 100 mg capsule per dose, preferably before the main meals. Pediatric dosing is specific, calculated by body weight at 1.5 mg/kg per dose, TID. The granules must be thoroughly mixed with food or water and administered immediately.

A core procedural instruction is that Racenil must be administered in conjunction with Oral Rehydration Therapy (ORT). Treatment should continue until two normal stools are recorded, but the course of use is strictly limited and must not exceed seven days. Dosage adjustment is not necessary for older adults, but caution is advised in adults with renal or hepatic impairment due to limited clinical data.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Racenil

This section summarizes the official clinical research and studies conducted on Racenil (Racecadotril) as reported in medical literature and by regulatory bodies. It is intended to provide a neutral overview of the evidence base.


Evidence for Acute Diarrhea in Adults

The understanding of Racenil's use in adults is primarily based on Randomized Controlled Trials (RCTs) and systematic reviews/meta-analyses that combine data from multiple trials. These studies were designed to monitor the effects of the medicine on adult outpatients experiencing acute, sudden-onset watery diarrhea. Research examined key outcomes related to the duration of the diarrheal episode and measured stool frequency and volume over short periods.

In these research scenarios, the findings describe patterns observed in the studies where groups receiving Racenil reported measurements related to the time to symptom resolution compared to groups who received a placebo. The evidence suggests patterns related to symptom progression over placebo. The results apply only to the populations studied and do not provide insight into chronic watery diarrhea.


Evidence for Acute Diarrhea in Children and Infants

Racenil was studied for its use in pediatric patients, including infants older than three months of age, in multiple RCTs and Systematic Reviews. The trials often evaluated the medicine when used in addition to standard Oral Rehydration Solution (ORS). The main outcomes research examined included total volume of stool output over a defined period (e.g., 48 hours), the duration of the diarrheal episode, and the length of hospital stay for children who were admitted.

Findings indicate that some studies report measurements related to stool output in the first 48 hours in the observed pediatric groups, where differences were measured compared to control groups. However, when combining and comparing the available evidence, findings were mixed across studies on certain key endpoints, such as the overall impact on the time until symptom resolution. Therefore, the evidence quality varies across studies.


Evidence Consistency and Research Gaps

Overall, the research describes a broad evidence landscape. For adults, the evidence suggests a consistent short-term pattern related to the duration of symptoms when compared to placebo. Conversely, for children, the findings were mixed, and evidence quality varies across some key outcomes.

Major research gaps include the lack of robust data on long-term outcomes. Research examining temporary physiological imbalance in other special groups, such as individuals with underlying chronic gastrointestinal conditions or women who are pregnant, is limited, underscoring a need for more data in the regulatory research record.

Key Studies & References

  1. Racecadotril Efficacy in the Symptomatic Treatment of Adult Acute Diarrhoea: A Systematic Review and Meta-Analysis
  2. A Comprehensive Comparison of the Efficacy and Tolerability of Racecadotril with Other Treatments of Acute Diarrhea in Adults
  3. AWMSG SECRETARIAT ASSESSMENT REPORT Racecadotril (Hidrasec) 10 mg and 30 mg granules for oral suspension (Regulatory Assessment)
  4. Racecadotril in the Treatment of Acute Diarrhoea in Adults. An Individual Patient Data Based Meta-Analysis

Frequently Asked Questions (FAQ)

Common questions about Racenil (FAQ)

Q: How is Racenil different from other similar treatments?

Racenil is classified as an antisecretory agent, which is distinct from some other diarrhea treatments. Its mechanism of action, as defined in regulatory documents, is described as reducing the excessive secretion of water and electrolytes in the intestine without affecting the movement or transit time of the gut.

Q: What is the general safety profile of Racenil based on official reports?

Official reports and clinical studies indicate that Racenil is generally well-tolerated when used for the short-term treatment of acute diarrhea. The safety profile, as described in some studies, was observed to be similar to a placebo (an inactive substance).

Q: Does Racenil interact with common over-the-counter pain relievers?

Official regulatory data indicates a low potential for clinically relevant pharmacokinetic interactions, meaning it indicates a low potential for changing how other medicines are processed by the body. No specific interactions with common over-the-counter pain relievers, such as acetaminophen or ibuprofen, are currently documented in the official labeling.

Q: Can Racenil be taken at the same time as other prescription medications?

Regulatory data indicates the medicine did not modify the kinetics of co-administered substances such as Loperamide in studies. However, official documents advise caution for individuals taking Angiotensin-Converting Enzyme (ACE) inhibitors, as co-administration is associated with an increased risk of a serious reaction called angioedema.

Q: Is Racenil considered a first-line treatment option?

Racenil is officially authorized for the symptomatic treatment of acute watery diarrhea in adults and children. It is often prescribed for use as an addition to standard Oral Rehydration Solution (ORS), which remains the main treatment for fluid loss.

Q: What are the risks of stopping Racenil suddenly?

Regulatory documents do not describe specific adverse effects resulting from a sudden cessation of the medicine. The treatment course is already limited and defined to address acute symptoms, continuing only until two normal stools are recorded and not exceeding seven days.

Q: What is the difference between the brand name Racenil and a generic version?

Racenil is the brand name for the active ingredient, Racecadotril. Generic versions contain the exact same active ingredient and are required by regulatory bodies to meet the same standards for quality, safety, and effectiveness as the brand-name product.

Q: Does Racenil need to be taken with food, or can it be taken on an empty stomach?

The condition of use for the capsules, as described in official documents, is to be taken preferably before the main meals. Taking the medicine with food is documented to delay the time it takes for the active substance to reach its maximum concentration in the blood, though the overall absorption (exposure) is not changed.

Q: Can Racenil affect the effectiveness of birth control pills?

Official regulatory data indicates a low potential for pharmacokinetic interactions, as the medicine does not significantly interfere with the body's major metabolic enzymes. Based on this, no specific effect on the effectiveness of oral contraceptives is documented.

Q: Is Racenil a cure for the condition it treats?

Racenil is officially described as providing symptomatic relief for acute watery diarrhea. This means its purpose is to address the severe symptoms of excessive fluid loss and help restore fluid balance, rather than curing the underlying cause of the condition.

Q: How long does it typically take for Racenil to start working?

Pharmacological studies indicate that the inhibitory effect on the intestinal enzyme begins relatively quickly, approximately 30 minutes after taking the medicine by mouth. This action results in a rapid effect to reduce the amount of fluid secreted into the gut.

Q: Is a delay in the effect of Racenil considered normal?

While the medicine is intended for rapid symptomatic relief, the duration of use is determined by clinical improvement, specifically continuing treatment until two normal stools are recorded. Official documents advise against its use if the diarrhea is associated with high fever or bloody stools.

Q: Can Racenil cause unexpected or rare side effects that people should know about?

Official labeling lists certain reactions classified as 'Frequency Not Known,' which are very rare but serious events identified through post-marketing surveillance. These include severe hypersensitivity reactions like Angioedema (swelling of the face or throat) and Severe Cutaneous Adverse Reactions (SCARs).

Q: Is it possible to be allergic to Racenil?

Official labeling restricts the use of Racenil (contraindicated) for individuals who have a known hypersensitivity (an allergy) to the active substance, Racecadotril, or any of the other ingredients in the product formulation.

Q: What is the evidence that Racenil is better than a placebo?

Research reviewed by regulatory bodies, specifically randomized controlled trials in adults, suggests a consistent short-term pattern in which measured outcomes related to the duration of symptoms were observed in the group receiving Racenil compared to the placebo group.

Q: Does Racenil cause dependence or addiction?

The active metabolite of Racenil does not cross the blood-brain barrier at typical doses. Because it does not act on the central nervous system, it is not classified as a controlled substance and does not carry a risk of dependence or addiction.

Q: Is Racenil safe to take if I am driving or operating machinery?

Regulatory labeling states that patients must consider any effects, such as headache or drowsiness (which have been reported), before driving or operating machinery.

Q: What should I do if I notice a side effect that is not listed in the patient information?

Official documents advise contacting a doctor or pharmacist if any side effects are experienced, including those not listed in the patient information leaflet. This process helps ensure continued monitoring of the medicine's safety profile.

Q: How does Racenil affect my body compared to no treatment at all?

Racenil is described as an antisecretory agent that targets the intestinal lining to limit the excessive output of fluid and electrolytes during acute diarrhea. This action helps to aid the body's process of restoring normal fluid balance.

Q: Is it okay to stop taking Racenil if I start feeling better?

The official course of use is defined as continuing treatment until two normal stools are recorded. This regimen is important for addressing the acute symptoms, and the entire course of use is strictly limited, not to exceed seven days.

Q: Is Racenil available as a generic medicine?

Racenil is a brand name for the active ingredient, Racecadotril. The substance Racecadotril is available under various brand names and may be available as a generic version in different regions, subject to local regulatory approval.

Q: Is it true that Racenil can affect my sleep?

The medicine is not specifically associated with sleep disorders like insomnia in the official labeling. However, other side effects, such as headache, have been reported in the official safety information.

Q: Is Racenil used to treat other conditions besides the main one it's approved for?

Racenil is officially authorized solely for the symptomatic treatment of acute watery diarrhea. Regulatory documents do not address or recommend its use for any other medical conditions or diagnoses.

Q: What if I have an existing heart condition; can I still take Racenil?

There is no general contraindication for heart conditions. However, caution is specifically advised for patients taking ACE inhibitors, a common class of heart and blood pressure medicine, due to a documented increased risk of angioedema.

Q: Does Racenil change how other medications are absorbed by the body?

Regulatory assessments indicate a low potential for clinically relevant interactions. The medicine does not modify the protein binding of highly-bound drugs, which relates to how they are transported in the bloodstream.

Q: Is there a specific time of day Racenil should be taken for the best effect?

The medicine is prescribed for administration three times daily (TID) at regular intervals. For adults, the recommendation is to take the medicine preferably before the main meals, without mandating a specific time of day.

Q: What is the official risk classification of Racenil for use in children?

Racenil is authorized for use in children aged three months and older. A key restriction is that it is not to be administered to children who have pre-existing hepatic (liver) or renal (kidney) impairment due to a lack of specific safety data in these populations.

Q: Is Racenil a controlled substance?

Based on its mechanism of action and official classification as an antisecretory agent, Racenil is not designated as a controlled substance in the major regulatory schedules.

Q: Why is Racenil only available by prescription?

Racenil is typically classified as a Prescription-Only Medicine (POM) in many regions. This regulatory status is assigned because the medicine requires professional oversight for diagnosis, correct administration guidance, and monitoring of potential risks and interactions by a healthcare provider.

Q: Can Racenil affect blood pressure or heart rate?

The medicine is intended to have a localized effect in the intestine. While an interaction with ACE inhibitors carries a risk of angioedema that can affect the cardiovascular system, clinical trials do not commonly list direct effects on blood pressure or heart rate.

How should Racenil be stored and disposed of?

How to Store and Dispose of Racenil?

The official labeling defines specific conditions for the storage and disposal of Racenil (racecadotril) to ensure product stability and safety.

Storage Requirements

Condition Requirement
Temperature Store below 30 C.
Protection Must be protected from light and moisture.
Packaging Keep in the original container, which must remain tightly closed.
Child Safety Must be kept out of the sight and reach of children.

Disposal

Unused or expired product must not be used after the expiration date printed on the package. The medicine must be disposed of according to local regulations or a pharmaceutical take-back scheme. Regulatory guidelines also stipulate that the product should not be thrown into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Racenil found in:

A-Z Index: